Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Nvelop Therapeutics Inc.
Headquarters: Cambridge, MA, United States of America
Website: N/A
Year Founded: 2022
Status: Merged
See Emerging Company Profile .
BioCentury | Mar 12, 2025
Discovery & Translation
Science Spotlight: Killing the mesenchymal precursors that drive cancer progression
BioCentury’s roundup of translational innovations also includes blood detection of pregnancy complications, BBB-crossing antibodies, and more
BioCentury | Dec 19, 2024
Discovery & Translation
Science Spotlight: Platelets as targeted protein degraders
BioCentury’s roundup of translational innovations also includes ribonucleoproteins delivery and fine-tuning TCR specificity
BioCentury | Dec 17, 2024
Deals
Candid strikes trio of T cell engager partnerships for autoimmunity
BioCentry’s Deals Report also features AbbVie acquiring Nimble, Nvelop-Chroma forming nChroma, and BMS canceling Century, Immatics deals
BioCentury | Dec 12, 2024
Deals
Nvelop, Chroma merger creates opportunity for targeted epigenome editors
Nvelop CEO Jeff Walsh will lead nChroma, which has $75M in new funding and a lead for HBV
BioCentury | Aug 30, 2024
Emerging Company Profile
Nvelop: Delivering gene editors to specific cells via virus-like particles
Propelled by $100M in seed funding, Cambridge, Mass.-based biotech is developing dual virus-like particle platforms from two gene editing pioneers
BioCentury | Jul 30, 2024
Product Development
Venturing beyond AAVs and LNPs to deliver therapeutic cargo
Dozens of companies aim to avoid immunogenicity and improve tissue-specificity
BioCentury | Apr 12, 2024
Finance
Venture report: Torl doubles its series B funding in Deep Track-led B2
Plus: PureTech’s Seaport launches, and updates from Nvelop, D3 Bio and more
Items per page:
1 - 7 of 7